Background. Cytoreductive surgery (CRS) and hyper-
The combination of radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can improve cancer-specific survival (CSS) in well-selected patients with peritoneal carcinomatosis (PC) of colorectal (CRC) or appendix tumors. 1 The outcome depends on multiple factors, such as the subtype of the primary tumor, the extent of carcinomatosis as defined by the peritoneal cancer index (PCI), and the radicality of surgery (completeness of cytoreduction [CC] score). 2 Modern systemic therapy has made tremendous advances, and recent regimens-for example, the combination of FOLFOXIRI and bevacizumab-provide a median progression-free and overall survival (OS) of 12 and 31 months, respectively. 3 However, a previous subgroup analysis of 2 randomized trials suggests an impaired survival for patients with PC compared to other hematogenous metastatic sites. 4 Despite the availability of a randomized trial, the benefit of CRS/HIPEC over modern systemic chemotherapy alone has not yet been proven. 5, 6 This is mostly due to methodologic shortcomings, such as the availability of novel agents for the control group, and different operative strategies or selection criteria. For CRC and appendicular tumors, however, there is evidence from multicenter databases and case series showing better OS for colorectal patients and long-term disease-free survival (DFS) for lowmalignant appendix tumors. 2, 7 Furthermore, it has been shown that this maximally invasive procedure can be performed with acceptable mortality and morbidity rates. 8 As a consequence, CRS/HIPEC became a treatment option for many patients with peritoneal surface malignancies.
The critical question today is the selection of patients for CRS/HIPEC to avoid unnecessary procedures in patients who will not benefit from surgical treatment. Preoperatively known clinical disease criteria may help select patients. This is probably the true benefit of analyses of patient registry outcomes while still awaiting results from randomized trials.
We retrospectively analyzed CSS and DFS of a patient cohort with PC from appendiceal or CRC origin and performed univariate and multivariate analysis to identify factors predicting outcome in regard to CSS and DFS. Furthermore, we analyzed the recurrence patterns to gain a better understanding about disease relapse after CRS/ HIPEC.
METHODS
A complete cohort of patients with PC of CRC of appendiceal origin scheduled for CRS/HIPEC in our department between January 2009 and December 2014 was analyzed. The primary outcome was CSS from the date of the operation. Secondary outcomes were DFS, determination of patterns of recurrence, and identification of factors predicting CSS and DFS. The study was approved by the responsible ethics committee (KEK-ZH-Nr. 2016-00118) of the cantonal authorities in Zurich, Switzerland.
Patients were selected for CRS/HIPEC after clinical assessment and exclusion of extra-abdominal tumor manifestations by positron emission tomography/computed tomography. All patients were presented in a multidisciplinary tumor board before treatment. Patients with CRC or high-grade (HG) appendiceal tumors received standard-ofcare perioperative chemotherapy based on leucovorin, 5-fluorouracil, irinotecan and/or oxaliplatin in combination with monoclonal antibodies targeting angiogenesis where appropriate. Patients with low-grade (LG) appendix tumors were directly operated. The group of LG appendiceal neoplasms corresponds to the entity of diffuse peritoneal adenomucinosis (DPAM) according to the classification of Ronnett et al. 9 The HG appendix tumor group includes mucinous tumors with high cellularity (peritoneal mucinous carcinoma, PMCA) and adenocarcinomas of intestinal or signet-ring type. Anesthesia was conducted with propofol and volatile anesthetics combined with thoracic epidural anaesthesia as described previously. 10 HIPEC was performed with an open abdomen/colosseum technique as specified elsewhere, using 1.5% glucose peritoneal dialysis solution for perfusion. 11, 12 Mitomycin C (30 mg/m 2 ) and doxorubicin (15 mg/m 2 ) were used in combination in all cases. A complete procedure was defined as radical CRS (CC score of 0 for HG appendix tumors/CRC and CC score of 0 or 1 in case of LG appendiceal neoplasms/DPAM) followed by HIPEC in full concentration at 42°C over 90 min. Follow-up included clinical examinations, tumor markers, and computed tomographic scans every 6 months. Adjuvant chemotherapy was provided according to recommendations of an interdisciplinary tumor board.
Statistics
Continuous data are provided as median ± interquartile range (IQR 
RESULTS

Patient Characteristics
Overall, 113 patients with PC of either appendiceal origin (n = 71, 31 LG and 40 HG tumors) or CRC (n = 42) were operated between January 2009 and December 2014. Patients had a median age of 52 years (IQR 43-59) and with an equal gender incidence (56 male and 57 female patients). Mean follow-up at time of analysis was 28 months. A complete procedure was possible in 76 patients (67.3%). Reasons for incomplete interventions were preoperative underestimation of PC by imaging modalities and inability to perform a complete resection. More precisely, in 12 patients the abdomen was closed after laparotomy or laparoscopy and initial inspection, 10 patients received surgical cytoreduction without HIPEC, and 15 patients had CRS/HIPEC but without achieving a CC score of 0. Overall morbidity rate was 41.7%. Major complications, defined according to ClavienDindo IIIB or higher (need for reoperation or intensive care unit referral), occurred in 12 patients (10.6%). 13 No 90-day mortality was observed. Table 1 summarizes the details of the patient characteristics and surgical procedures. 
CSS after Complete CRS/HIPEC
After radical CRS/HIPEC, the median CSS for patients with CRC (n = 29) was 40 months, while the median CSS for HG appendix tumors (n = 19) has not been reached. All patients (n = 28) with LG appendix tumors were still alive at the time of analysis (n = 28) (Fig. 1a) . Three-year CSS rates were 74% for HG appendix tumors and 66% for CRC. Survival of LG appendix tumors was significantly better than for HG (p = 0.004) or CRC (p = 0.001) patients. Remarkably, there was no difference between HG appendix and CRC patients (p = 0.614). In contrast, survival was significantly impaired in incompletely resected patients, with a median CSS of only 13 months for patients with CRC (n = 13; p B 0.001) and 24 months for HG appendix tumors (n = 21; p = 0.011). None of the three patients with incompletely resected DPAM had died of disease at last follow-up.
DFS after Complete CRS/HIPEC
DFS after 3 years was 26% in patients with CRC, and 38 and 96% for HG and LG appendix tumors, respectively. Median time until recurrence of disease was 12 months for CRC and 19 months for HG appendix neoplasms, while the corresponding value has not been reached for LG appendix tumors after 60 months (Fig. 1b) . DFS of LG appendix tumors was significantly better than for HG or CRC tumors (p B 0.001 for both). In contrast, there was no difference between HG appendix and CRC patients (p = 0.254).
Patterns of Recurrence after Complete CRS/HIPEC
A total of 34.5% of patients with PC from CRC remained free of disease, while 65.5% developed recurrence during the observation period. Only 13.8% of patients showed isolated locoregional recurrence. The majority presented with a combination of locoregional and distant recurrence (24.1%) or distant relapse only (27.4%). However, recurrence included the peritoneal cavity in up to 38% of the patients, reflecting the role a local disease control. Patients with appendix tumors showed a recurrence rate of 31.9%. Most recurrences were isolated in the peritoneal cavity; only three patients developed distant metastases. CSS was most impaired in patients with multifocal recurrence compared to patients without disease relapse (p = 0.008), reflecting the aggressive tumor biology in this subgroup, while patients with distant recurrence only (p = 0.056) had a slightly better survival. An isolated peritoneal relapse pattern was associated with the best course of the 3 recurrence patterns (p = 0.288).
Univariate and Multivariate Analysis of Predictive Factors
Subsequent univariate and multivariate analysis was performed on completely resected HG tumors (n = 48; 29 CRC and 19 HG appendix tumors) only, as no patient with DPAM died and only 3 experienced disease recurrence (Table 3) .
DISCUSSION
The present study observed and confirmed a survival benefit in selected patients with PC from CRC and appendix tumors after CRS/HIPEC. Among patients after complete CRS/HIPEC, we identified a PCI of C10 as negative prognostic factor for CSS, while nodal involvement is a risk factor for shortened CSS and DFS. To our surprise, major postoperative complications emerged as a significant variable influencing both recurrence and survival. Patients with PC of colorectal origin can reach a median CSS of 40 months. Those results compare to data published by other specialized groups reporting a median CSS of 33 months, which is clearly superior to the median OS of 12 months only in patients with PC treated with conventional chemotherapy. 2, 4, 14 Our survival data also reinforce the results of the first randomized controlled trial comparing CRS/HIPEC versus chemotherapy alone in patients with PC from CRC, which showed a survival benefit of a year. 5, 6 The median DFS of 12 months in our patients is also comparable to reported results. 2, 14 The outcome for patients with HG appendix tumors is comparable to CRC, with only 37% alive and 32% free of disease after 5 years. These results are inferior compared to published data, which report a 5-year OS of 59%. 7 However, this cohort included PMCA only, while our analysis incorporated patients with PMCA as well as intestinal and signet-ring type adenocarcinomas. While no definite data regarding the specific outcome after CRS/HIPEC of those HG subgroups are available, it has been shown in prior studies that outcomes for intestinal and signet-ring adenocarcinomas are worse than for PMCA. [15] [16] [17] In contrast, in patients with LG appendicular neoplasms, we observed excellent long-term CSS and DFS. Although DPAM is normally not a rapidly progressing disease, patient morbidity still was high before the upcoming CRS/ HIPEC. Treatment consisted of repeated surgical debulking. In one of the most recent reports, median DFS after CRS only was 24 months. 18 OS within our patients with DPAM was excellent in our analysis, as has been reported from several other centers. 7, 19 Median DFS has not yet been reached but confirms the data of other groups, which show periods between 35 and 98 months. 7, 19 As a result of the convincing data, CRS/HIPEC can today be considered the standard of care for DPAM.
Our analyses furthermore confirmed the results of previous articles identifying positive nodal status as being an important predictor of shortened DFS and CSS. 20, 21 The observed patterns of recurrence agree with previous reports demonstrating the worst survival for a combined recurrence type. 22 Additionally, the amount of peritoneal involvement significantly influences CSS. Yet this finding is not new, and it undermines once more a key principle of CRS: the imperative to achieve a complete resection. 6 The critical question for adequate selection remains the maximal tumor load for CRS/HIPEC. While in patients with DPAM curative resections are possible with maximal peritoneal dissemination, an increasing body of evidence demonstrates a significantly decreased survival rate for patients with CRC and a PCI of [15 or [17, respectively. 23,24 A new and substantial finding of our analysis is the identification of major postoperative complications as a significant risk factor influencing CSS and DFS (Fig. 2) . It is noteworthy that this impaired survival does not refer to mortality in the postoperative course but rather to longterm oncologic outcome. Large case series have shown that CRS/HIPEC can be performed with acceptable morbidity and mortality rates, which could be confirmed by analysis of our own patient cohort. 8, 25 However, major complications being a risk factor for long-term survival has only come into focus recently, with conflicting results. 26 A recent study found postoperative complications requiring interventions to be predictive of early recurrence in CRC patients and consequently impaired OS. 27 In contrast, another study could not find any influence of a prolonged intensive care unit stay or readmission on long-term survival. 28 There are several possible explanations for this observation. Patients necessitating extensive resections have an elevated risk of microscopic incomplete resections and therefore an increased risk of early tumor recurrence. 27 More extensive resections with prolonged operation time and colonic resections also place the patient at an increased risk for postoperative complications like fistulas or infections. 29 Infectious complications are among the most frequent after CRS/HIPEC. 25, [29] [30] [31] Extensive surgical trauma as well as sepsis lead to a phase of immunosuppression termed compensatory anti-inflammatory response syndrome after an initial proinflammatory state known as systemic inflammatory response syndrome. 32, 33 Occurrence of complications might therefore disturb the already delicate postoperative immunological balance in these patients, multiplying the postoperative immunosuppressive state. It has furthermore been demonstrated that HIPEC itself can induce immunosuppression as a result of hematologic toxicity and systemic absorbance of the chemotherapeutics used. 34 Factors of HIPEC, which influence the extent of immunosuppression, are the chemotherapeutic agents used as well as performance of splenectomy, which so far yields conflicting results regarding whether it mitigates or increases hematologic toxicity. [34] [35] [36] When we consider these data together, we speculate that the already disturbed immunological balance is further shifted toward immunosuppression with the occurrence of infection-entailed major complications. This might block effective elimination of remaining systemic or peritoneal tumor cells by cytotoxic T cells and natural killer cells. This state of immunosuppression might also enable circulating tumor cells, which can be detected in up to 50% of patients before CRS/HIPEC, to escape elimination and more easily seed to new, different locations. 37 This would , defined as Clavien-Dindo IIIB or higher, had significantly worse long-term outcome with median CSS of 34 months only compared to patients without major complications (n = 70) (p B 0.026). Vertical bars imply censoring event. Analysis was performed via construction of Kaplan-Meier curves. Mantel-Cox log rank test was used to test for differences between groups directly affect DFS and CSS. Further research on this topic is highly warranted.
Our study has several restrictions. It is limited by its retrospective nature. The small sample size and low eventto-variable ratio prevent further subgroup analysis during Cox regression analysis and could potentially be prone to bias. Conclusions might therefore require confirmation in additional patient cohorts.
However, the factors identified in this study might prove helpful in the individual preoperative assessment and selection of patients. Major complications should be avoided whenever possible-not only in regard to perioperative morbidity and mortality, but also in the interest of the long-term oncologic outcome of patients with PC.
CONCLUSIONS
Outcomes after complete CRS/HIPEC are excellent for LG appendix tumors. A majority of well-selected patients with PC from CRC and HG appendix tumors will have a survival benefit.
Extent of peritoneal tumor spread, lymph node invasion, and major perioperative chemotherapy affect long-term CSS after CRS/HIPEC. Adequate selection of patients and avoidance of major complications whenever possible therefore remains critical for CRS/HIPEC.
